Format
Sort by

Send to

Choose Destination

Selected items

Items: 5

1.

Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.

Kitamura Y, Goodfellow PJ, Shimizu K, Nagahama M, Ito K, Kitagawa W, Akasu H, Takami H, Tanaka S, Wells SA Jr.

Oncogene. 1997 Jun 26;14(25):3103-6.

2.

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.

Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M, Mian C, Siggelkow H, Hüfner M, Wohllk N, Opocher G, Dvořáková S, Bendlova B, Czetwertynska M, Skasko E, Barontini M, Sanso G, Vorländer C, Maia AL, Patocs A, Links TP, de Groot JW, Kerstens MN, Valk GD, Miehle K, Musholt TJ, Biarnes J, Damjanovic S, Muresan M, Wüster C, Fassnacht M, Peczkowska M, Fauth C, Golcher H, Walter MA, Pichl J, Raue F, Eng C, Neumann HP; International RET Exon 10 Consortium.

Hum Mutat. 2011 Jan;32(1):51-8. doi: 10.1002/humu.21385.

PMID:
20979234
3.

Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis.

Hansford JR, Mulligan LM.

J Med Genet. 2000 Nov;37(11):817-27. Review.

4.

Familial medullary thyroid carcinoma with noncysteine ret mutations: phenotype-genotype relationship in a large series of patients.

Niccoli-Sire P, Murat A, Rohmer V, Franc S, Chabrier G, Baldet L, Maes B, Savagner F, Giraud S, Bezieau S, Kottler ML, Morange S, Conte-Devolx B; French Calcitonin Tumors Group (GETC).

J Clin Endocrinol Metab. 2001 Aug;86(8):3746-53.

PMID:
11502806
5.

Pyrosequencing technology as a method for the diagnosis of multiple endocrine neoplasia type 2.

Kruckeberg KE, Thibodeau SN.

Clin Chem. 2004 Mar;50(3):522-9. Epub 2004 Jan 12.

Supplemental Content

Support Center